Metamark Genetics, Inc. Announces Three New Board Members
CAMBRIDGE, Mass., Sept. 23 /PRNewswire/ — Metamark Genetics, Inc., a privately held, oncology-focused molecular diagnostics company, announced today the appointment of three new Board Members. As a result, the Metamark Board of Directors will increase to seven members with expanded expertise in diagnostics, clinical oncology, and international business affairs.
Metamark’s new Board additions include Dr. Gregory C. Critchfield, M.D., M.S., a highly successful healthcare business executive with extensive diagnostic and biopharmaceutical experience in large and small companies. Until his retirement in March 2010, Dr. Critchfield was President and Board Member of Myriad Genetic Laboratories, Inc., where he was responsible for building its scientific, medical, and commercial capabilities and launching seven novel molecular diagnostic products across a variety of technology platforms.
Metamark also announces the addition of Dr. Mansoor Raza Mirza, M.D., a leading practicing European oncologist with extensive experience in gynecologic oncology to the Board. From 2000-2008, Dr. Mirza was Chief Oncologist at Odense University Hospital in Denmark. Since 2008 Dr. Mirza has held the position of Chief Oncologist at The Finsen Centre, Copenhagen University Hospital, Denmark.
Metamark’s third Board addition is Mr. Slava Smolokowski, a successful international businessman and entrepreneur, and a Metamark investor. Mr. Smolokowski built a large Europe-based oil trading business which later became the cornerstone for Mercuria Energy Group. Mercuria has grown to become one of the largest global energy trading companies in the world. More recently, Mr. Smolokowski has formed an international investment group with broad interests in finance, technology, upstream oil and gas, real estate, media, and the arts.
In announcing the Board additions, Metamark’s Chairman and CEO Kenneth E. Weg commented, “The scope and depth of experience and expertise the new directors bring will be important drivers of success for Metamark in its goal of becoming a major innovator and global leader in oncology molecular diagnostics.”
Cautionary Note Regarding Forward-Looking Statements
This press release, and information contained on Metamark’s website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark’s strategies and future plans, prospects and results, are forward-looking statements. The words “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.
SOURCE Metamark Genetics, Inc.